VRDN FY 2024 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$302,000-3.8% YoY

Gross Profit

$302,000100.0% margin

Operating Income

-$299M-99018.2% margin

Net Income

-$270M-89387.1% margin

EPS (Diluted)

$-3.98

Cash Flow

Operating Cash Flow

-$232M

Free Cash Flow

-$233M

Stock-Based Comp.

$42M

Balance Sheet

Total Assets

$742M

Total Liabilities

$71M

Stockholders' Equity

$672M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$302,000	$314,000	-3.8%
Gross Profit	$302,000	$314,000	-3.8%
Operating Income	-$299M	-$254M	-17.5%
Net Income	-$270M	-$238M	-13.6%